Gilead Sciences, Inc.
GILD · Nasdaq
GILD · Nasdaq
The supplied consensus is Buy, backed by 24 analysts, with low, mean and high price targets all listed at $165, implying no spread in that snapshot. Post-results target actions point higher: Morgan Stanley raised its target to $183 while maintaining Overweight, and Truist’s Gregory Renza raised his target to $181 from $158 while keeping Buy. Morgan Stanley is the most bullish of the named analysts with an explicit updated target in the evidence; the supplied material does not identify the least bullish analyst for this week. The target revisions were upward after the upbeat quarter. The substantive disagreement is whether HIV-led sales growth and the raised sales outlook outweigh the lower EPS outlook and Biktarvy’s projected 2028 pricing headwind.
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| Morgan Stanley | — | $165 | -0.5% | Jul 27, 2026 | Open the report this row came from | |
| Leerink Partners | — | — | — | Jul 21, 2026 |
| HSBC Holdings plc | — | $155 | -6.6% | Jul 6, 2026 | Open the report this row came from |
